Despite the development of multiple AR signaling inhibitors (ARSI, including abiraterone, enzalutamide, darolutamide, and apalutamide) that have improved the clinical outcome for patients with advanced disease, treatment resistance is inevitable and advanced prostate cancer remains fatal (5). This evidence concerns the gene AR and prostate carcinoma.